The two aldosterone antagonists currently licensed for commercial use in the U.S are spironolactone and eplerenone. These drugs act in different ways and will be prescribed according to the cardiologist's findings.

Each has been shown to be life-saving in patients with advanced heart failure and are thought to be beneficial in certain patients with mild heart failure.

Patients undergoing treatment with these drugs are regularly monitored for potassium and renal function.